공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

펩티드 합성 시장 : 성장, 동향, 예측(2020-2025년)

Peptide Synthesis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 925331
페이지 정보 영문
US $ 4,250 ₩ 4,788,000 PDF (Single User License)
US $ 4,750 ₩ 5,352,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,760,000 PDF (Site License)
US $ 7,500 ₩ 8,451,000 PDF (Corporate License)

펩티드 합성 시장 : 성장, 동향, 예측(2020-2025년) Peptide Synthesis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 펩티드 합성 시장은 예측기간 중 약 12.5%의 CAGR로 성장할 것으로 예측됩니다. 암, 당뇨병, 비만 등 다양한 생활 습관병 치료의 응용 범위가 넓은 의약품이나 소비자 의료 업계에서 펩티드 채용이 급상승하고 있습니다. 예를 들면 2019년에 발표된 International Diabetes Federation 보고서에 의하면 약 4억 6,300만명이 당뇨병을 안고 생활하고 있으며, 2형 당뇨병은 당뇨병 중에서 가장 일반적인 종류로 세계 당뇨병의 약 90%를 차지하고 있습니다. 이와 같이 2형 당뇨병 환자수의 증가로 디펩티딜 펩티다제 4(DPP-4) 억제제, 글루카곤 유사 펩티드 1(GLP-1) 아날로그 등의 펩티드 의약품 수요가 증가하고 있으며, 이러한 질환에 대한 효율적인 약제를 합성하는 것이 예측기간 중 시장을 활성화시킬 가능성이 높은 상황입니다.

세계의 펩티드 합성(Peptide Synthesis) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 기술별·제품별·최종사용자별·지역별 시장 규모 추정과 예측, 경쟁 상황, 주요 기업 개요, 시장 기회 등의 정보를 제공합니다.


제1장 서론

  • 조사 성과
  • 조사 가정
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 바이오의약품 산업에서 게노믹스 및 프로테오믹스 연구개발을 위한 거액의 자금 조달에 따른 투자 증가
    • 강력한 펩티드 치료 파이프라인과 함께 펩티드 합성기의 급속한 기술 진보
  • 시장 성장 억제요인
    • 대규모 펩티드 합성에 관한 문제와 강력한 배포 네트워크의 결여
    • 펩티드 의약품의 적절한 투여 경로 개발 과제
  • Porter's Five Forces 분석
    • 신규 참여업체의 위협
    • 바이어/소비자의 협상력
    • 공급업체의 협상력
    • 대체 제품의 위협
    • 경쟁 격화

제5장 시장 세분화

  • 기술별
    • 고상
    • 액상
    • 하이브리드 및 재조합
  • 제품별
    • 장비
    • 시약과 소모품
    • 기타
  • 최종사용자별
    • 제약 및 바이오테크놀러지 기업
    • 수탁 개발 및 제조 조직(CDMO)
    • 학술 및 조사기관
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 상황

  • 기업 개요
    • AAPPTec
    • Anaspec Inc
    • Bachem Holding AG
    • Biotage AB
    • CEM Corporation
    • CSBio Company Inc
    • Gyros Protein Technologies AB
    • Merck KGaA
    • New England Peptide Inc
    • Thermo Fisher Scientific

제7장 시장 기회 및 향후 동향

KSM 20.05.25

The peptide synthesis market is expected to register a CAGR of 5.5 % over the forecast period.

Owing to the current COVID-19 situation, peptides are increasingly being developed and repurposed in search of therapeutics for the treatment of COVID-19. In February 2020, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less. As per the data on Clinical Trials.gov, in May 2020, 21 peptide drugs were in the development for the treatment of COVID-19, including 15 synthetic peptides for Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition where the lungs cannot provide the body's vital organs with enough oxygen, and other respiratory illnesses caused by SARS-Cov-2 infection.

The major propelling the growth of the market is a steep rise in the adoption of peptides in the pharmaceutical and consumer healthcare industries. The peptides have a wide range of applications in the treatment of various lifestyle disorders such as cancers, diabetes, and obesity. The increasing incidence of these metabolic and lifestyle disorders is paving the way for the application of peptide therapeutics in oncology and metabolic disorders. According to the International Diabetes Federation report published in 2020, around 463 million people were living with diabetes in 2019 and by 2045 the prevalence will reach 700 million. Among the prevalence Type 2 diabetes is the most common type of diabetes, accounting for around 90% of all diabetes globally. Diabetes mellitus (Type 2 diabetes) is a group of metabolic disorders of carbohydrate metabolism. Several peptide therapies such as Glucagon-like peptide-1amide release postprandially, which stimulates insulin secretion and is popular pancreatic therapy. Thus, due to the rise in the volume of the patient pool with Type 2 diabetes, the demand for peptides is expected to increase which is likely to fuel the market over the forecast period. Also, the increased research activities and novel product approvals due to the rise in funding for R&D and the advantages of advanced peptide synthesizers have further boosted the growth of the peptide synthesis market throughout the period. For instance, in 2018, Novartis and Amgen have received approval in European Union countries for Aimovig (erenumab), a calcitonin gene related-peptide inhibitor that helps in the treatment of migraine in adults. As per the Novartis, patients administered with erenumab during the clinical studies were reported with almost 50% reduction of migraine attacks. Thus, such significant developments in peptide drugs are expected to boost the demand.

Key Market Trends

Pharmaceutical & Biotechnology Companies is Expected to Hold the Significant Market Share Over the Forecast Period

Based on the end-user, pharmaceutical & biotechnology companies is expected to hold the significant market due to the increasing adoption of peptide for therapeutic development in this industry. The research and developments of peptide therapies are increasing as they are cost-effective, efficient, and have lower toxicity. These peptides are also a major part of the COVID-19 related research these days. Swiss-based Relief Therapeutics is conducting an FDA-approved clinical trial, which is part of the FDA's Coronavirus Treatment Acceleration Program (CTAP), at New York University Langone (NYU Langone Health) to assess the effect of Aviptadil, a patented synthetic form of a human vasoactive intestinal polypeptide (VIP) for COVID-19-related ARDS. New oral drugs are being developed by various pharmaceutical and biotechnology companies, which is expected to boost the demand for this segment.

For instance, in 2019, the US FDA approved Rybelsus oral tablets for controlling the blood sugar in Type-2 diabetes patients. It is a glucagon-like peptide (GLP-1) receptor protein treatment developed by Novo Nordisk. Also, in November 2019, AstraZeneca announced large-scale initiatives in China to advance global research and development (R&D) for innovative medicines including peptide therapies.All these developments are expected to propel the growth of the pharmaceutical & biotechnology companies end-user segment.

The graph below suggests that the prevelnace of diabetes is increasing in the world which is also fueling the demand for the treatment of this metabolic disorder, which in turn is expected to drive the market growth.

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the overall peptide synthesis market throughout the forecast period. The dominance is due to the growing prevalence of obesity with a rise in sedentary deskbound lifestyle and lack of proper diet along with physical activity resulting in various chronic diseases like diabetes in the United States necessitated the efficient treatment. For instance, according to the International Diabetes Federation in 2019, about 48 million adults in North America are living with diabetes and are expected to continue resulting in higher demand for peptide therapeutics driving the market in the region.

Furthermore, the increased availability of advanced healthcare infrastructure along with huge investments by the key players in this region to develop a new peptide synthesis technologies is also likely to fuel the market growth. Also, a favorable earlier approval of peptide drugs owing to the accelerated drug approval initiative by USFDA is also likely to fuel the market growth in this region across the forecast period contributing to its outstanding market share in the global peptide synthesis market.

Competitive Landscape

The peptide synthesis market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, research collaboration, while others are introducing new products to maintain their market share. For Instance, In May 2019, CEM Corporation launched Liberty PRO, the world's first-ever large-scale automated microwave peptide synthesizer. The system can synthesize 1 kg of crude peptide per batch utilizing reaction vessel, sizes up to 15 liters with unmatched purity, speed, and waste reduction fueling the market revenue share. Few of the major players currently dominating the industry in terms of revenue are AAPPTec, CSBio Company Inc, Biotage AB, Bachem Holding AG, and CEM Corporation.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Investments Along with Huge Funding for R&D of Genomics and Proteomics in Bio-pharmaceutical Industry
    • 4.2.2 Rapid Technological Advancements in Peptide synthesizers Coupled by Strong Peptide Therapeutics Pipeline
  • 4.3 Market Restraints
    • 4.3.1 Issues Pertaining to Large-scale Peptide Synthesis and Lack of Robust Distribution Network
    • 4.3.2 Challenges in Development of Peptides and Instability of the Peptides
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Technology
    • 5.1.1 Solid-Phase
    • 5.1.2 Liquid-Phase
    • 5.1.3 Hybrid & Recombinant
  • 5.2 By Product
    • 5.2.1 Equipment
    • 5.2.2 Reagents & Consumables
    • 5.2.3 Others
  • 5.3 By End-User
    • 5.3.1 Pharmaceutical & Biotechnology Companies
    • 5.3.2 Contract Development & Manufacturing Organization (CDMO)
    • 5.3.3 Academic & Research Institutes
  • 5.4 By Geography
    • 5.4.1 North America
      • United states
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Rest of the World


  • 6.1 Company Profiles
    • 6.1.1 AAPPTec
    • 6.1.2 Amgen Inc.
    • 6.1.3 Anaspec Inc
    • 6.1.4 Bachem Holding AG
    • 6.1.5 Biotage AB
    • 6.1.6 Bristol-Myers Squibb
    • 6.1.7 CEM Corporation
    • 6.1.8 CSBio Company Inc
    • 6.1.9 Eli Lilly and Company
    • 6.1.10 Ever Neuro Pharma GmbH
    • 6.1.11 Gyros Protein Technologies AB
    • 6.1.12 Merck KGaA
    • 6.1.13 New England Peptide Inc
    • 6.1.14 Pfizer Inc.
    • 6.1.15 Thermo Fisher Scientific


Back to Top
전화 문의